Highly active antiretroviral therapy (HAART) has revolutionized the therapy of human immunodeficiency virus disease, yet a substantial fraction of patients either never respond, or lose virologic control during the first 3 years of therapy. In this study, patients who have failed HAART are being treated with three experimental agents. The study has two major goals: to determine the response rate to these agents, and to determine what clinical and laboratory parameters, especially genotypic and phenotypic analysis, are useful for predicting response. Ultimately, a database of 300 patients is expected to be available for analysis.
|Falloon, Judith; Ait-Khaled, Mounir; Thomas, Deborah A et al. (2002) HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS 16:387-96|
|Falloon, J; Piscitelli, S; Vogel, S et al. (2000) Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 30:313-8|